Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
NCT ID: NCT06558227
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
90 participants
INTERVENTIONAL
2024-10-24
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
ZG005 10 mg/kg administered intravenously every 3 weeks (Q3w) + Bevacizumab (Avastin®) 15 mg/kg administered intravenously Q3w
ZG005 for Injection
10 mg/kg or 20 mg/kg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Group B
ZG005 20 mg/kg administered intravenously Q3w + Bevacizumab (Avastin®) 15 mg/kg administered intravenously Q3w
ZG005 for Injection
10 mg/kg or 20 mg/kg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Group C
Sintilimab 200 mg administered intravenously Q3w + Bevacizumab (达攸同®) 15 mg/kg administered intravenously Q3w
Sintilimab
200 mg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZG005 for Injection
10 mg/kg or 20 mg/kg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Sintilimab
200 mg administered intravenously Q3w
Bevacizumab
15 mg/kg administered intravenously Q3w
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
* Life expectancy ≥ 12 weeks.
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Wu
Role: STUDY_CHAIR
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hong Wu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZG005-005
Identifier Type: -
Identifier Source: org_study_id